^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.

Excerpt:
...HER2 low expression: IHC1+, IHC2+/FISH- Phase Ib dose-expanded study: Histologically or cytologically confirmed breast cancer patients who have failed to prior trastuzumab treatment....
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study

Published date:
11/22/2022
Excerpt:
Patients with HER2-expresssing advanced solid tumors who had failed prior standard of care therapies were enrolled...ORRs were observed at doses at or above 1.0 mg/kg with an ORR of 66.7% (4/6) at the recommended phase 2 dose (RP2D) of 2.3 mg/kg. Median duration of response (DoR) across all dose levels was 9.2 months (95%CI 5.6-NR)...FS-1502 was well-tolerated and demonstrated encouraging antitumor activity in both HER2-high and -low patients.
Trial ID: